Friday, 19 July 2019

LifeArc licenses lead stage molecules to Daiichi Sankyo

24 April 2019 | News

The licensing deal successfully concludes a research collaboration between LifeArc, Oxford University’s Nuffield Department of Clinical Neurosciences and Daiichi Sankyo.

image credit- pharmaceutical-journal.com

image credit- pharmaceutical-journal.com

LifeArc, one of the UK’s leading medical research charities, has signed a deal to license an ion channel drug discovery programme to Daiichi Sankyo Company, Limited.

Small molecules, optimised as part of the programme, are capable of affecting the sensitivity of neurons, show efficacy in treating pain and will undergo further pre-clinical development.

The licensing deal successfully concludes a research collaboration between LifeArc, Oxford University’s Nuffield Department of Clinical Neurosciences and Daiichi Sankyo.

Under the terms of the deal Daiichi Sankyo acquires an exclusive worldwide license to a discovery stage programme of small molecules with the potential to develop into novel treatments for intractable pain.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Blockchain offering a solution to the healthcare industry?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls